Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Feb 4;29(7):1413-20.
doi: 10.1016/j.vaccine.2010.12.039. Epub 2011 Jan 1.

A Phase 1 Study of a Meningococcal Native Outer Membrane Vesicle Vaccine Made From a Group B Strain With Deleted lpxL1 and synX, Over-Expressed Factor H Binding Protein, Two PorAs and Stabilized OpcA Expression

Affiliations
Clinical Trial

A Phase 1 Study of a Meningococcal Native Outer Membrane Vesicle Vaccine Made From a Group B Strain With Deleted lpxL1 and synX, Over-Expressed Factor H Binding Protein, Two PorAs and Stabilized OpcA Expression

P B Keiser et al. Vaccine. .

Abstract

This phase I clinical trial assessed the safety and immunogenicity of a native outer membrane vesicle (NOMV) vaccine prepared from an lpxL1(-) synX(-) mutant of strain 8570(B:4:P1.19,15:L8-5) of Neisseria meningitidis. Additional mutations enhance the expression of factor H binding protein variant 1 (fHbp v.1), stabilize expression of OpcA and introduce a second PorA (P1.22,14). Thirty-six volunteers were assigned to one of four dose groups (10, 25, 50 and 75 mcg, based on protein content) to receive three intramuscular injections at six week intervals with aluminum hydroxide adjuvant. Specific local and systemic adverse events were solicited by diary and at visits on days 2, 7, and 14 after each vaccination. Blood chemistries, complete blood count, and coagulation studies were measured on each vaccination day and again 2 and 14 days later. Blood for ELISA and serum bactericidal assays was drawn two and six weeks after each vaccination. The proportion of volunteers who developed a fourfold or greater increase in bactericidal activity to the wild type parent of the vaccine strain at two weeks after the third dose was 27 out of 34 (0.79, 95% C.I. 0.65-0.93). Against four other group B strains the response rate ranged from 41% to 82% indicating a good cross reactive antibody response. Depletion assays show contributions to bactericidal activity from antibodies to lipooligosaccharide (LOS), fHbp v.1 and OpcA.

Similar articles

See all similar articles

Cited by 52 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback